# 23rd International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents

> **NIH NIH R13** · LSU HEALTH SCIENCES CENTER · 2020 · $4,999

## Abstract

Abstract
This conference grant application requests funds to help support the 23nd International
Conference on Kaposi's Sarcoma Herpesvirus and Related Agents in 2020. Our annual
conference will bring together researchers and clinicians working on the oncogenic human
herpesvirus, Kaposi's sarcoma herpesvirus (KSHV), and other closely related pathogens. KSHV
is the etiology agent of Kaposi's sarcoma (KS), which is still one of the most prevalent cancers in
Africa, especially in HIV-1 infected individuals. The funds will be used to reduce the conference
registration costs for outstanding pre- and post-doctoral trainees, historically under-represented
minorities, and scientists from lower income countries, especially those from Africa who study
oncogenic DNA viruses and the cancers associating with these viruses. The goals of these
meetings are consistent with the mission statements of the NIH, NCI, NIAID, and NIDCR, namely,
to advance and promote the pace of research on infections associated with human cancer and
other diseases, including in the setting of HIV-AIDS. The main KSHV conference will be held in
Dar es Salaam, Tanzania, from the afternoon of June 22 through June 25, 2020. With an
additional day, June 26, for a training workshop to engage both established researchers and
trainees, clinicians and basic researchers, to interact and develop collaborations on translational
research projects. All remaining costs for the conference will be raised from registration fees paid
by the conferees and contributions from host institutions, foundations, and pharmaceutical and
biotechnology companies. The major focus of the KSHV meeting is the biology of oncogenic
herpesviruses and associated human diseases, with specific emphasis on viral pathogenesis,
viral latency and reactivation, viral gene expression and replication, host responses to infection,
epidemiology, vaccine development, therapeutic intervention, clinical and translational research.
In addition to KSHV, studies related to herpesvirus saimiri (HVS), murine herpesvirus-68 (MHV-
68), and rhesus rhadinovirus (RRV) will be presented. The 23nd International Conference on
Kaposi's Sarcoma- Herpesvirus and Related Agents will mark a new quarter century of research
on KSHV since the discovery of this virus in 1994, a new century to engage clinicians and
researcher from the continent where infection by KSHV and its associated malignancy is the
highest in the world

## Key facts

- **NIH application ID:** 10525451
- **Project number:** 7R13CA250288-02
- **Recipient organization:** LSU HEALTH SCIENCES CENTER
- **Principal Investigator:** Charles Wood
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $4,999
- **Award type:** 7
- **Project period:** 2020-04-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10525451

## Citation

> US National Institutes of Health, RePORTER application 10525451, 23rd International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents (7R13CA250288-02). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10525451. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*